Hyderabad: In the first global study to test the effectiveness of monoclonal antibody cocktails (MAB) against the feared Delta variant, Hyderabad-based AIG Hospital along with the Asian Healthcare Foundation, CCMB Hyderabad and Institute of Life Sciences, found that therapy was able to neutrize the Delta variant and reduce 100% severe disease and death in deltas infected with high-risk individuals.
This study is titled ‘Effectiveness of the Regen-Cov Antibody Cocktail Against Variant B.1.617.2 (Delta) of SARS-COV-2: Cohort Study’, which has been published in the journal Treatment of Internal Peer-Review, found high.
The patient’s risk, which was infected with the Delta variant, which was treated with a cocktail of MAB, which was launched by Roche earlier this year, also showed a faster symptom resolution.
Describing the findings, Chairman of the AIG Hospital Dr.
D Nageshwar Reddy said that 75% of patients who received MAB therapy became negative RT-PCR on 78th day and 78% of patients were released from their clinical symptoms such as fever and cough after day 7.
Also, he said, there were no participants suffering from severe illness or died, there was no increase in the marker of the inflammatory (which caused severe illness) and in follow-up there were no patients who reported post-covid syndrome.
‘Monoclonal Antibody Cocktail Neutralize Delta variant’
